Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo …
…, G de Smedt, L Leopold, R Trefiglio, B Woodfall - The Lancet, 2007 - thelancet.com
Background Antiretroviral agents active against drug-resistant HIV-1 are needed for
treatment-experienced patients. The aim of this trial was to assess the efficacy, safety, and …
treatment-experienced patients. The aim of this trial was to assess the efficacy, safety, and …
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo …
…, G de Smedt, B Baeten, G Beets, R Sinha, B Woodfall - The Lancet, 2007 - thelancet.com
Background TMC125 (etravirine) is a non-nucleoside reverse-transcriptase inhibitor (NNRTI)
with activity against NNRTI-resistant HIV-1 in phase IIb trials. The aim of DUET-2 is to …
with activity against NNRTI-resistant HIV-1 in phase IIb trials. The aim of DUET-2 is to …
[HTML][HTML] Lack of antiviral activity of darunavir against SARS-CoV-2
…, C Buyck, M Van Loock, B Woodfall… - International Journal of …, 2020 - Elsevier
Objectives Given the high need and the absence of specific antivirals for treatment of COVID-19
(the disease caused by severe acute respiratory syndrome-associated coronavirus-2 […
(the disease caused by severe acute respiratory syndrome-associated coronavirus-2 […
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies
…, M Peeters, MP de Béthune, G De Smedt, B Woodfall… - Aids, 2010 - journals.lww.com
Objective: To refine the genotypic and phenotypic correlates of response to the nonnucleoside
reverse transcriptase inhibitor etravirine. Design: Initial analyses identified 13 etravirine …
reverse transcriptase inhibitor etravirine. Design: Initial analyses identified 13 etravirine …
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
…, M Peeters, G Picchio, J Vingerhoets, B Woodfall… - Aids, 2009 - journals.lww.com
Objective: To evaluate the efficacy, safety and virologic resistance profile of etravirine (TMC125),
a next-generation nonnucleoside reverse transcriptase inhibitor, over 48 weeks in …
a next-generation nonnucleoside reverse transcriptase inhibitor, over 48 weeks in …
Short-term antiviral activity of TMC278–a novel NNRTI–in treatment-naive HIV-1-infected subjects
…, MPP de Béthune, M Peeters, B Woodfall - Aids, 2006 - journals.lww.com
Objective: To evaluate antiviral activity, pharmacokinetics, tolerability and safety of TMC278,
a non-nucleoside reverse transcriptase inhibitor (NNRTI), when given as a 25, 50, 100 or …
a non-nucleoside reverse transcriptase inhibitor (NNRTI), when given as a 25, 50, 100 or …
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
…, R Haubrich, S Nijs, J Vingerhoets, B Woodfall… - 2010 - journals.sagepub.com
Background Durable efficacy and long-term safety of antiretroviral therapy are important goals
in the management of treatment-experienced patients. The 96-week efficacy and safety of …
in the management of treatment-experienced patients. The 96-week efficacy and safety of …
An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance
…, K Arasteh, K De Dier, M Peeters, B Woodfall… - Aids, 2003 - journals.lww.com
The development of resistance to any of the currently licensed non-nucleoside reverse
transcriptase inhibitors (NNRTI) invariably leads to cross-resistance to the drugs in that class. …
transcriptase inhibitors (NNRTI) invariably leads to cross-resistance to the drugs in that class. …
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers
…, TN Kakuda, V Sekar, B Woodfall… - Antiviral …, 2007 - journals.sagepub.com
… Volunteers - Monika Schöller-Gyüre, Thomas N Kakuda, Vanitha Sekar, Brian Woodfall,
Goedele De Smedt, Eric Lefebvre, Monika Peeters, Richard M Hoetelmans, 2007 … Brian Woodfall …
Goedele De Smedt, Eric Lefebvre, Monika Peeters, Richard M Hoetelmans, 2007 … Brian Woodfall …
A pharmacokinetic study of etravirine (TMC125) co‐administered with ranitidine and omeprazole in HIV–negative volunteers
…, MP Bouche, M Peeters, B Woodfall… - British journal of …, 2008 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Drug–drug interactions with acid‐suppressing
agents were previously described with several other antiretroviral drugs. • …
agents were previously described with several other antiretroviral drugs. • …
